Glycated HSA Rhodamine Boronic Acid small molecule (tool compound)

Fluorescent boronic acids like these enable the detection and identification of individual glycated proteins in complex samples through gel electrophoresis.

Contributors

Inventor	Institute
Marta P. Pereira Morais	University of Bath

Cat. #:	154474
Research Fields:	Cancer;Cell biology

Alternate name:	AGEs
Product description:	Protein glycation, also known as non-enzymatic glycosylation, has been implicated in various disease states and is therefore an important biomarker for ageing and age-related chronic diseases such as diabetes, cardiovascular diseases, autoimmune diseases, cancer, and Alzheimer's disease. However their analysis is challenging due to the complexity of the protein-carbohydrate adducts. Fluorescent boronic acids like these enable the detection and identification of individual glycated proteins in…
Additional notes:	This small molecule has been used to identify glycated proteins in human serum, insect hemolymph, and mouse brain homogenates.

Primary target:	Advanced Glycation Endproducts (AGE); specifically Glycated Human Serum Albumin (HSA). Also binds ApoA-I protein.

Shipping conditions:	Dry Ice

References:	Pereira Morais et al. 2013. Sci Rep. 3:1437. PMID: 23531746.

Unfortunately this tool is not currently available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151712

CDK7 inhibitor BS-181 Small Molecule (Tool Compound)

Key Info

Cat. #:	151712
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	BS-181 is stable in vivo with a plasma elimination half-life in mice of 405 minutes after i.p. administration of 10 mg/kg. BS-181 inhibits the growth of MCF-7 xenografts in the nude mice model in a dose-dependent manner, with 25% and 50% reduction in tumor growth after 2 weeks of treatment at 10 mg/kg/day and 20 mg/kg/day, respectively without apparent toxicity. BS-181 is a small molecule inhibitor of CDK7 in a cell-free environment, which displays more potential activity than roscovitine with IC 50 of 510 nM. Among the CDKs and other 69 kinases from many different classes, BS-181 shows high inhibitory selectivity for CDK7, inhibits CDK2 at concentrations lower than 1 ÎźM which being inhibited 35-fold less potently (IC50 with 880 nM) than CDK7, shows slight inhibition for CDK1, CDK4, CDK5, CDK6 and CDK9 with IC50 values higher than 3.0 ÎźM, and only shows inhibition for several kinases from other classes at high concentrations (>10 ÎźM). BS-181 promotes cell cycle arrest and inhibits the cancer cell growth of a range of tumor types, including breast, lung, prostate and colorectal cancer with IC50 in the range of 11.5-37 ÎźM. In MCF-7 cells, BS-181 inhibits the phosphorylation of the CDK7 substrate RNA polymerase II COOH-terminal domain (CTD), and promotes cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines.

View Tool

151831

Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound)

Key Info

Cat. #:	151831
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	In Panc-1 subcutaneous xenograft model, orally administration of CRT0066101 at the dosage of 80 mg/kg/d for 24 days significantly suppressed pancreatic cancer growth. Moreover, when CRT0066101 reached its peak concentration (12 Îźmol/L) in tumor model, the expression of activated PKD1/2 in the treated tumor explants was substantially decreased. It was concluded that CRT0066101 given orally at 80 mg/kg/d for 21 days in Panc-1 orthotropic model suppressed tumor growth potently in vivo. Clinical…

View Tool

151832

LIMK inhibitor CRT0105950 Small Molecule (Tool Compound)

Key Info

Cat. #:	151832
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The compounds exhibit low uM potency in breast cancer cells showing dose dependent inhibition of phosphorylation of the LIMK substrate cofilin. Treatment of MDA-MB-231 breast cancer cells with the compounds significantly reduces their ability to invade a matrigel plug in an inverse in vitro invasion assay. Furthermore, the inhibitors effectively reduce fibroblast-led collective invasion in a co-culture organotypic model.

View Tool

151879

AKR1C3 inhibitor CRT0083914 Small Molecule (Tool Compound)

Key Info

Cat. #:	151879
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing

View Tool

152788

Phosphatidylinositol-4-phosphate 5-kinase inhibitor PIP5K Small Molecule (Collaborative Toolkit)

Key Info

Cat. #:	152788
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing

View Tool

By Category

By Cancer Type

More

Glycated HSA Rhodamine Boronic Acid small molecule (tool compound)

Contributors

Images

Related Tools for Small molecules

Tool enquiry